Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

IPAX-2 : A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18-65Age 18-65

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal

Systemic therapy | Brain and spinal cordGlioblastoma (GBM)

Trial Overview Read MoreRead more

This phase I study is seeking to evaluate the safety of increasing radioactive dose levels of 131I-TLX101 when given in addition to best standard of care treatment in people with newly diagnosed glioblastoma.

This trial is treating patients with glioblastoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma

Commercial Sponsor

Telix International Pty Ltd


Eligible participants will receive 131I-TLX101, administered via intravenous infusion in ascending doses, as well as 18F-FET, also administered intravenously.

Recruiting Hospitals Read MoreRead more

Austin Health
Ms Samantha Chakar
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.